Figure F-91 is titled “Change in CAPS for anticonvulsants compared with placebo: Sensitivity analysis including studies with high risk of bias.” The figure displays a forest plot reporting the weighted mean difference in CAPS scores stratified by divalproex versus placebo, tiagabine versus placebo, and topiramate versus placebo. The plot depicts greater reductions in CAPS scores for patients treated with placebo than divalproex (2 trials, weighted mean difference 4.90, 95% CI −4.75 to 14.54, I2=22.8%). On the other hand, there were greater reductions in CAPS scores for patients treated with tiagabine (1 trial, weighted mean difference −0.50, 95% CI −7.12 to 6.12) or topiramate (4 trials, weighted mean difference −15.29, 95% CI −19.00 to −11.57, I2=0.0%) than placebo. The overall analysis favored anticonvulsants (weighted mean difference −6.12, 95% CI −14.37 to 2.14, I2=79.7%).

Figure F-91Change in CAPS for anticonvulsants compared with placebo: Sensitivity analysis including studies with high risk of bias

Note: Hamner et al., 2009 and Lindley et al., 2007 were rated as high risk of bias.

Timing of outcome assessment: 8 weeks (Davis, 2008), 10 weeks (Hamner, 2009), 7 weeks (Lindley, 2007); 12 weeks (Davidson, 2007; Akuchekian, 2004; Tucker, 2007; Yeh, 2011).

From: Appendix F, Meta-Analysis

Cover of Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD)
Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD) [Internet].
Comparative Effectiveness Reviews, No. 92.
Jonas DE, Cusack K, Forneris CA, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.